Privia Health (PRVA) Research & Development (2020 - 2026)

Privia Health has reported Research & Development for 7 years, with the latest figure at $8.0 million in Q2 2026.

• On a quarterly basis, Research & Development rose 17.59% year-over-year to $8.0 million in Q2 2026; TTM through Jun 2026 was $29.5 million, a 8.48% increase from a year earlier, with the FY2025 full-year figure at $27.1 million, up 2.61% from the prior year.
• Research & Development was $8.0 million for Q2 2026 at Privia Health, down from $8.1 million in the prior quarter.
• The five-year high for Research & Development was $8.1 million in Q1 2026, with the low at $4.7 million in Q1 2022.
• Average Research & Development over 5 years is $6.3 million, with a median of $6.5 million recorded in 2024.
• The largest YoY upside for Research & Development was 46.39% in 2022 against a maximum downside of 56.89% in 2022.
• Over 5 years, Research & Development stood at $5.2 million in 2022, then advanced by 20.8% to $6.2 million in 2023, then rose by 3.41% to $6.5 million in 2024, then retreated by 0.2% to $6.4 million in 2025, then advanced by 24.08% to $8.0 million in 2026.
• The last three Research & Development figures came in at $8.0 million (Q2 2026), $8.1 million (Q1 2026), and $6.4 million (Q4 2025), per Business Quant data.